Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Melatonin Metabolism Abnormality in Patients With Schizophrenia or Schizoaffective Disorder Treated With Olanzapine and Melatonin Dose Finding for the Correction of the Metabolic Abnormality

NCT00512070 is registered in ClinicalTrials.gov with Seattle Institute for Biomedical and Clinical Research as lead sponsor.

NCT NCT00512070
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00512070 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Melatonin Metabolism Abnormality in Patients With Schizophrenia or Schizoaffective Disorder Treated With Olanzapine and Melatonin Dose Finding for the Correction of the Metabolic Abnormality
Lead sponsor
Seattle Institute for Biomedical and Clinical Research
Phase
Not applicable
Overall status
Completed
Start date
July 31, 2007
Completion date
December 31, 2024
Enrollment
40 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bipolar disorder, metabolic syndrome, obesity, schizoaffective disorder, schizophrenia